Johnson & Johnson files for CAPLYTA approval in bipolar mania

Key highlights
  • Johnson & Johnson submitted a supplemental New Drug Application to the U.S. FDA for CAPLYTA (lumateperone) in adults with bipolar I mania.
  • The application is supported by two Phase 3 trials of once-daily 42 mg CAPLYTA over three weeks.
  • Both trials showed significant improvement versus placebo, with manic symptoms improving from Day 3.
  • CAPLYTA is currently approved for schizophrenia, bipolar depression and adjunctive treatment of major depressive disorder in adults.

FDA application

Johnson & Johnson submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking approval of CAPLYTA (lumateperone) for manic or mixed episodes associated with bipolar I disorder in adults. If approved, this would be the medicine’s fifth approved adult use. It is not currently approved for bipolar mania.

Phase 3 results

The application is based on two randomized, double-blind, placebo-controlled Phase 3 studies. Adults received once-daily CAPLYTA 42 mg or placebo for three weeks. In both studies, CAPLYTA met the primary and key secondary endpoints, showing significant improvement in manic symptoms and overall illness severity compared with placebo. Symptom improvement was observed by Day 3 and continued through Week 3. The medicine was well tolerated, with low discontinuation rates and a safety profile consistent with previous studies.

Current indications

CAPLYTA is approved for adults with depressive episodes associated with bipolar I or II disorder, either alone or with lithium or valproate; as an adjunct to antidepressants for major depressive disorder; and for schizophrenia.

Source: J&J

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

10 November 2026
Johnson & Johnson reports positive Phase 3 mania results for CAPLYTA

A second pivotal study found improvement in symptoms by Day 3; the findings will support a planned US regulatory submission.

8 September 2026
Johnson & Johnson to present neuropsychiatry data at Psych Congress 2026

24 abstracts at Psych Congress will report Phase 3 CAPLYTA data in bipolar mania, SPRAVATO analyses on anhedonia, seltorexant MDD+insomnia results, and LAI real‑world studies.

4 May 2026
Johnson & Johnson: CAPLYTA tops adjunctive MDD antipsychotics in network meta-analysis

Network meta-analysis of 10 trials found an adjunctive atypical antipsychotic superior on MADRS change, response, remission and CGI‑S, with no significant weight gain and favorable tolerability.

11 November 2026
Lilly reports one-year data on Taltz and Zepbound combination

ACR50 response reached 43.7% versus 15.7% with Taltz alone; exploratory results also showed metabolic and patient-reported improvements.

25 October 2026
Johnson & Johnson reports 75% RECIST response for JNJ-6143 in advanced prostate cancer

Phase 1 data show 75% imaging response and deep PSA declines at 50 mg; most adverse events were mild–moderate and 50 mg will advance to Phase 2.